Method for providing diagnosis of cancer using seprase as a marker

US8980573B2 · kind B2 · utility

Assignee

• Roche Diagnostics Operations, Inc. · US

Inventors

• Wolfgang Rollinger · Polling, DE
• Johann Karl · Peißenberg, DE
• Jarema Peter Kochan · Towaco, US
• Markus Roessler · Germering, DE
• Michael Tacke · Munich, DE

Key dates

• Filing date: Jun 2, 2010
• Grant date: Mar 17, 2015
• Expiry date: Jan 20, 2032

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2333/96411
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

The present invention relates to a method aiding in the assessment of cancer. It discloses the use of the human fibroblast activation protein (FAP/seprase) as a universal marker of different cancer types. Seprase aids in the assessment of pulmonary or lung cancer (LC) or of colon cancer, e.g., of non-small cell lung carcinoma (NSCLC) or colorectal cancer (CRC), but also likely of other specific types of cancer. Such specific cancer types are, e.g., esophagus, head and neck cancer, stomach cancer, bile duct cancer, pancreas cancer, kidney cancer, cervix cancer, ovary cancer, breast cancer, bladder cancer, endometrium cancer or prostate cancer. Furthermore, it especially relates to a method for assessing cancer from a liquid sample, derived from an individual by measuring seprase in said sample. Measurement of seprase can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.